このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Wearable HRV Biofeedback for Stress in Dementia Caregivers (CARE-COHERENCE)

Low-cost Wearable Heart Rate Variability Biofeedback as a Nurse-led Intervention to Reduce Stress in Informal Caregivers of People With Dementia: a Prospective Controlled Non-randomized Interventional Trial

This study will evaluate whether a nurse-led heart rate variability (HRV) biofeedback programme supported by a low-cost wearable sensor reduces autonomic dysregulation and perceived stress in informal caregivers of people with dementia. Participants will be prospectively allocated, without randomization, at the day-care-centre level. Before enrolment, the six centres will be characterised according to centre size, estimated number of eligible caregivers and expected recruitment volume, and arranged into three approximately matched pairs. One centre in each pair will implement CARE-COHERENCE and the other will serve as a concurrent comparison centre under a pre-specified operational implementation plan. Follow-up will continue for 12 months.

調査の概要

詳細な説明

Approximately 100 informal caregivers of older people with dementia attending one of six participating day-care centres will be enrolled. The intervention group will receive an 8-week HRV-biofeedback programme in addition to usual caregiver support. The comparison group will receive usual caregiver support during the 12-month study period and will be offered access to programme materials after completion of the final assessment. The primary outcome is change in resting root mean square of successive differences (RMSSD) from baseline to 6 months. Perceived stress is the key secondary outcome. Assessments occur at baseline, 8 weeks, 6 months and 12 months.

研究の種類

介入

入学 (推定)

100

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Cantabria
      • Santander、Cantabria、スペイン
        • 募集
        • Hospital Universitario Marqués de Valdecilla
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adult (18 years or older) self-identified informal, unpaid caregiver of an older person with a clinical diagnosis of dementia attending one of the participating day-care centers.
  • Providing an average of at least 28 hours of unpaid care per week for a minimum of 3 months.
  • Able to understand study procedures and provide written informed consent.
  • Able to use a smartphone and a simple wearable device, independently or with brief study support.

Exclusion Criteria:

  • Persistent or clinically significant cardiac arrhythmia preventing reliable interbeat-interval analysis.
  • Pacemaker-dependent rhythm or another condition that, in the investigator's judgment, precludes valid heart rate variability assessment.
  • Current participation in formal heart rate variability biofeedback or structured resonance-frequency breathing training, or equivalent training within the previous 3 months.
  • Severe uncontrolled psychiatric illness or cognitive impairment precluding informed consent or meaningful participation.
  • Concurrent enrollment in another structured stress-reduction intervention trial.
  • Note: use of heart rate-modifying medication, including beta-blockers, is not an exclusion criterion. Medication use is documented prospectively and considered in prespecified sensitivity analyses.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:CARE-COHERENCE HRV biofeedback program

Participants receive an 8-week nurse-led heart rate variability (HRV) biofeedback program in addition to usual caregiver support. At program entry, an individual resonance frequency is determined using paced-breathing trials across a prespecified range of approximately 4.5 to 6.5 breaths per minute. The active phase comprises four weekly nurse-led sessions of approximately 60 minutes during weeks 1-4, followed by structured supported home practice during weeks 5-8. Sessions cover the physiological rationale for HRV biofeedback, paced breathing at the selected training frequency, interpretation of simple wearable feedback, management of common practice difficulties, and a brief positive-emotion self-regulation strategy. Participants are encouraged to practice approximately 10 minutes twice daily, or to reach a minimum accumulated practice target of 70 minutes per week. One booster contact occurs at month 3.

Nurse-delivered behavioral self-regulation training combining individualized resonance-frequency paced breathing with real-time HRV feedback from a low-cost wrist- or chest-worn sensor capable of recording interbeat intervals, paired with a compatible training application. Dose: four supervised sessions of approximately 60 minutes in weeks 1-4, delivered individually or in small groups, followed by supported home practice in weeks 5-8 (target 10 minutes twice daily, or at least 70 accumulated minutes per week), plus one booster contact at month 3. Training frequency is set per participant during an initial paced-breathing assessment across approximately 4.5-6.5 breaths per minute. A brief positive-emotion self-regulation strategy is included. The device model, firmware, and application version are prespecified before recruitment and held constant where possible. Adherence is derived from device and application logs and a participant practice log.

他の名前:
  • 共鳴周波数呼吸トレーニング
  • CARE-COHERENCE program
介入なし:Usual caregiver support

Participants continue to receive usual caregiver support, including routine clinical care, information, and standard services available through the participating day-care centers and other routine health and social care services. They do not receive structured resonance-frequency breathing training or HRV biofeedback from the study team at any point during the 12-month study period. After the 12-month assessment, participants in this group will be offered access to the CARE-COHERENCE educational materials and a program orientation session.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in resting RMSSD
時間枠:Baseline and 6 months

Root mean square of successive differences (RMSSD) derived from a standardised resting interbeat-interval recording obtained with the study wearable sensor and processed according to a prespecified HRV analysis protocol. Higher values indicate greater vagally mediated heart rate variability.

Baseline and 6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in perceived stress (Perceived Stress Scale, PSS-10)
時間枠:Baseline, 8 weeks, 6 months and 12 months

Perceived stress measured with the 10-item Perceived Stress Scale (PSS-10). Total score ranges from 0 to 40. Higher scores indicate greater perceived stress; a decrease indicates improvement. Analyzed as change from baseline and as the follow-up value adjusted for the baseline score. This is the key secondary outcome.

Baseline, 8 weeks, 6 months and 12 months
Maintenance of resting RMSSD at 12 months
時間枠:Baseline and 12 months

Root mean square of successive differences (RMSSD, in milliseconds) derived from a standardized resting interbeat-interval recording obtained with the study wearable sensor and processed with the prespecified HRV analysis pipeline. Higher values indicate greater vagally mediated heart rate variability. Assesses whether any intervention effect on the primary outcome is maintained six months after the primary endpoint.

Baseline and 12 months
Change in caregiver burden (Zarit Burden Interview, ZBI-22)
時間枠:Baseline, 8 weeks, 6 months and 12 months

Caregiver burden measured with the 22-item Zarit Burden Interview. Total score ranges from 0 to 88. Higher scores indicate greater burden; a decrease indicates improvement.

Baseline, 8 weeks, 6 months and 12 months
Change in resting SDNN
時間枠:Baseline, 8 weeks, 6 months and 12 months

Standard deviation of normal-to-normal interbeat intervals (SDNN, in milliseconds) from the same standardized resting recording used for the primary outcome. Higher values indicate greater overall heart rate variability.

Baseline, 8 weeks, 6 months and 12 months
Change in mean resting heart rate
時間枠:Baseline, 8 weeks, 6 months and 12 months

Mean heart rate in beats per minute derived from the standardized resting interbeat-interval recording.

Baseline, 8 weeks, 6 months and 12 months
Change in well-being (WHO-5 Well-Being Index)
時間枠:Baseline, 8 weeks, 6 months and 12 months

Well-being measured with the five-item WHO-5 Well-Being Index. The raw score ranges from 0 to 25 and is multiplied by 4 to give a percentage score from 0 to 100. Higher scores indicate better well-being; an increase indicates improvement.

Baseline, 8 weeks, 6 months and 12 months
Change in anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, HADS)
時間枠:Baseline, 8 weeks, 6 months and 12 months

Symptoms measured with the Hospital Anxiety and Depression Scale. The HADS-Anxiety and HADS-Depression subscales are reported separately; each ranges from 0 to 21. Higher scores indicate more severe symptoms; a decrease indicates improvement.

Baseline, 8 weeks, 6 months and 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Carmen Sarabia Cobo、University of Cantabria

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月1日

一次修了 (推定)

2028年4月30日

研究の完了 (推定)

2028年10月31日

試験登録日

最初に提出

2026年11月5日

QC基準を満たした最初の提出物

2026年11月5日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data underlying the results reported in the primary publication, together with the data dictionary, may be made available to qualified researchers whose proposed use has been approved by the study team. Data will be shared subject to a data-sharing agreement, applicable ethics committee requirements, and EU General Data Protection Regulation and Spanish data-protection law. Requests should be addressed to the corresponding author.

IPD 共有時間枠

Beginning 6 months after publication of the primary results report, with no specified end date.

IPD 共有アクセス基準

Requests from qualified researchers with a methodologically sound proposal, reviewed by the study team, and subject to a signed data-sharing agreement and to applicable ethics and EU/Spanish data-protection requirements. Requests should be sent to the corresponding author.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する